Companies are at the forefront of beta cell replacement therapeutic research for diabetes Evotec receives € 3 Million payment from Sanofi Milestone further demonstrates advancement of EVT Innovate initiative “TARGETBCD”

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a next generation anti-infectives portfolio